Equities Analysts Set Expectations for ZNTL Q3 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued on Friday, November 15th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.67) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.76) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.68) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Several other research firms have also recently issued reports on ZNTL. Guggenheim decreased their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a research note on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $3.05 on Monday. The business has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $5.33. The firm has a market capitalization of $217.34 million, a price-to-earnings ratio of -1.22 and a beta of 1.74. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.07.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC grew its stake in shares of Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after purchasing an additional 11,748 shares during the last quarter. XTX Topco Ltd grew its position in Zentalis Pharmaceuticals by 8.7% in the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock worth $714,000 after buying an additional 15,597 shares during the last quarter. Quarry LP acquired a new position in Zentalis Pharmaceuticals in the third quarter worth approximately $55,000. Paloma Partners Management Co acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.